Sooma Medical provides the EU MDR‑approved Sooma tDCS™ system, a portable transcranial direct current stimulation device that delivers non‑invasive, drug‑free brain‑stimulation therapy for major depressive disorder and chronic pain. The solution combines a certified hardware headset with a cloud‑based platform for remote protocol management, real‑time session monitoring, and data‑driven clinical adjustments, enabling clinics and hospitals to scale treatment and reduce patient wait times.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with major depressive disorder and chronic pain often face limited access to effective, non‑pharmacological treatments, leading to long clinic wait times, reliance on medication with side effects, and difficulty scaling care across diverse healthcare settings.
Solution
Sooma Medical offers the Sooma tDCS™ system, a portable transcranial direct current stimulation device that delivers clinically validated brain‑stimulation therapy for depression and chronic pain. The device integrates remote protocol management, allowing clinicians to monitor treatment sessions online, adjust parameters based on data, and make evidence‑based decisions without requiring patients to attend frequent in‑person visits. As the first EU MDR‑approved tDCS system, it provides a drug‑free, non‑invasive option that can be administered in clinics, hospitals, or at home under professional supervision. Clinical data show symptom improvement in as little as three weeks, and the system’s scalability helps increase patient throughput while reducing queue lengths. The solution combines high‑quality hardware manufactured to ISO 13485 standards with a cloud‑based analytics platform for secure data storage and outcome tracking.
Target Audience
Primary customers are mental health clinics, pain management centers, and hospitals seeking a non‑pharmacological therapy for depression and chronic pain, as well as healthcare providers in over 35 countries looking to expand access to neuromodulation treatments.
Features
- Portable tDCS headset with built‑in safety controls and ISO 13485‑certified manufacturing
- Remote treatment protocol management and real‑time session monitoring via a secure cloud platform
- Clinician dashboard offering automated progress reports, symptom scoring, and adjustable stimulation parameters
- EU MDR‑approved status ensuring compliance with European medical device regulations
- Drug‑free, non‑invasive stimulation targeting depressive and chronic pain pathways with documented efficacy in peer‑reviewed studies
- Scalable workflow that supports both in‑clinic and at‑home administration under professional oversight